AM-679 (cannabinoid)

This article is about the cannabinoid agonist. For the FLAP inhibitor, see AM-679 (FLAP inhibitor).

AM-679 (cannabinoid)

Systematic (IUPAC) name
(2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	335160-91-3 N
ChemSpider	25991468 Y
Chemical data
Formula	C20H20INO
Molecular mass	417.283 g/mol
SMILES Ic1ccccc1C(=O)c(c2ccccc23)cn3CCCCC
InChI InChI=1S/C20H20INO/c1-2-3-8-13-22-14-17(15-9-5-7-12-19(15)22)20(23)16-10-4-6-11-18(16)21/h4-7,9-12,14H,2-3,8,13H2,1H3 Y Key:GAJBHYUAJOTAEW-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a K_i of 13.5nM at CB₁ and 49.5nM at CB₂. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB₁ agonists AM-694 and AM-2233, and the selective CB₂ agonist AM-1241. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.

See also

• RCS-4
• AM-694
• AM-2233